At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,707 enrolled
Drug / intervention
Quadrivalent seasonal influenza vaccine GSK2282512A +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older
In Brief
A Phase 3 clinical trial evaluating Quadrivalent seasonal influenza vaccine GSK2282512A, FluLavalTM-VB, and 1 other intervention for Influenza. Completed, enrolled 1,707 participants across 12 sites in 3 countries.
Detailed Summary
This study is designed to test the immunogenicity and safety of an investigational influenza vaccine, in adults compared to two other influenza vaccines. This study will also evaluate the lot-to-lot consistency of three vaccine lots.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesCanada, Mexico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2010
Enrollment StartOct 2010
Primary CompletionJan 2011
Study CompletionJun 2011
TodayJul 2026
First PostedSep 9, 2010
Enrollment StartOct 1, 2010
Primary CompletionJan 25, 2011
Study CompletionJun 24, 2011
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 15.8 years ago
Interventions
Quadrivalent seasonal influenza vaccine GSK2282512Abiological
Single intramuscular dose
FluLavalTM-VBbiological
Single intramuscular dose
FluLavalTM-YBbiological
Single intramuscular dose